Amine Belhabri

1.2k total citations
40 papers, 458 citations indexed

About

Amine Belhabri is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Amine Belhabri has authored 40 papers receiving a total of 458 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Hematology, 11 papers in Genetics and 11 papers in Oncology. Recurrent topics in Amine Belhabri's work include Acute Myeloid Leukemia Research (22 papers), Chronic Myeloid Leukemia Treatments (8 papers) and Lymphoma Diagnosis and Treatment (7 papers). Amine Belhabri is often cited by papers focused on Acute Myeloid Leukemia Research (22 papers), Chronic Myeloid Leukemia Treatments (8 papers) and Lymphoma Diagnosis and Treatment (7 papers). Amine Belhabri collaborates with scholars based in France, Belgium and Netherlands. Amine Belhabri's co-authors include Philippe A. Cassier, D Fière, Marie Castets, Norbert Vey, Xavier Thomas, Mauricette Michallet, E Archimbaud, Jean‐Pierre Magaud, C Charrin and Stefan Suciu and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Amine Belhabri

34 papers receiving 451 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Amine Belhabri France	14	272	147	112	95	92	40	458
Rayaz Ahmed India	12	286 1.1×	122 0.8×	105 0.9×	104 1.1×	110 1.2×	55	459
Keiren Kirkland United Kingdom	11	297 1.1×	84 0.6×	105 0.9×	162 1.7×	61 0.7×	24	458
Wenyuan Mai China	13	326 1.2×	199 1.4×	50 0.4×	81 0.9×	66 0.7×	44	442
Carla Filì Italy	10	310 1.1×	104 0.7×	63 0.6×	52 0.5×	57 0.6×	24	436
Silvia Manfroi Italy	13	302 1.1×	167 1.1×	96 0.9×	103 1.1×	155 1.7×	34	491
Masatoshi Sakurai Japan	13	204 0.8×	105 0.7×	114 1.0×	118 1.2×	33 0.4×	69	497
S. K. China	11	176 0.6×	85 0.6×	61 0.5×	46 0.5×	105 1.1×	23	337
Erica Simeone Italy	12	284 1.0×	135 0.9×	60 0.5×	67 0.7×	124 1.3×	22	391
R. Pasold Germany	7	256 0.9×	110 0.7×	189 1.7×	110 1.2×	83 0.9×	12	471
Motohiro Tsuzuki Japan	10	384 1.4×	343 2.3×	45 0.4×	58 0.6×	108 1.2×	27	518

Countries citing papers authored by Amine Belhabri

Since Specialization

Citations

This map shows the geographic impact of Amine Belhabri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amine Belhabri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amine Belhabri more than expected).

Fields of papers citing papers by Amine Belhabri

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amine Belhabri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amine Belhabri. The network helps show where Amine Belhabri may publish in the future.

Co-authorship network of co-authors of Amine Belhabri

This figure shows the co-authorship network connecting the top 25 collaborators of Amine Belhabri. A scholar is included among the top collaborators of Amine Belhabri based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amine Belhabri. Amine Belhabri is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tavernier, Emmanuelle, Jérôme Cornillon, Martin Carré, et al.. (2024). Azacitidine and Venetoclax As a Salvage Therapy for Relapse after Allogeneic Transplantation for Acute Myeloid Leukemia : A Multicentric Study from French Auraml Group. Blood. 144(Supplement 1). 1518–1518. 2 indexed citations

Garciaz, Sylvain, Justine Decroocq, Sarah Bertoli, et al.. (2022). Long-Term Survival of Acute Myeloid Leukemia Responding Patients Who Stopped Azacytidine and/or Venetoclax Because of Poor Tolerance or Physician Choice: A Retrospective Multicenter Study from the French Innovative Leukemia Organization (FILO). Blood. 140(Supplement 1). 6147–6148. 2 indexed citations

Decroocq, Justine, Sylvain Garciaz, Amine Belhabri, et al.. (2022). Therapy related myeloid neoplasms (t-MNs) following PARP inhibitors (PARPi): Real-life experience.. Journal of Clinical Oncology. 40(16_suppl). 7057–7057. 1 indexed citations

Nicolas‐Virelizier, Emmanuelle, Chiara Russo, Olivia Pérol, et al.. (2021). Individualised physical activity programme in patients over 65 years with haematological malignancies (OCAPI): protocol for a single-arm feasibility trial. BMJ Open. 11(6). e046409–e046409. 1 indexed citations

Belhabri, Amine, Yves Bertrand, Catherine Sebban, et al.. (2019). Pattern of Care and Outcomes of Adolescent and Young Adults with Lymphoma Treated in the Rhône-Alpes Region. Journal of Adolescent and Young Adult Oncology. 8(6). 684–696.

Neste, Éric Van Den, Marc André, Thomas Gastinne, et al.. (2018). A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma. Haematologica. 103(5). 840–848. 42 indexed citations

Cassier, Philippe A., Marie Castets, Amine Belhabri, & Norbert Vey. (2017). Targeting apoptosis in acute myeloid leukaemia. British Journal of Cancer. 117(8). 1089–1098. 63 indexed citations

Huet, Sarah, Pascale Cony‐Makhoul, Maël Heiblig, et al.. (2014). Major Molecular Response Achievement in CML Patients Can Be Predicted by BCR-ABL1/ABL1 or BCR-ABL1/GUS Ratio at an Earlier Time Point of Follow-Up than Currently Recommended. PLoS ONE. 9(9). e106250–e106250. 22 indexed citations

Fossard, Gaëlle, Emmanuelle Nicolas‐Virelizier, François Ducray, et al.. (2013). Utility Of Post Therapy Brain Surveillance Imaging In The Detection Of Primary CNS Lymphoma (PCNSL) Relapse. Blood. 122(21). 933–933. 1 indexed citations

10.

Le, Quoc‐Hung, Youcef Chelghoum, Mohamed Elhamri, et al.. (2008). Prognostic Index for Older Adult Patients with Newly Diagnosed Acute Myeloid Leukemia: The Edouard Herriot Hospital Experience. 2(3). 198–204. 9 indexed citations

11.

Le, Quoc‐Hung, Youcef Chelghoum, Mohamed Elhamri, et al.. (2007). Prognostic Index for Older Adult Patients with Newly Diagnosed Acute Myeloid Leukemia: The Edouard Herriot Hospital Experience.. Blood. 110(11). 4352–4352. 2 indexed citations

12.

Suciu, Stefan, G. Verhoef, Boris Labar, et al.. (2003). The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921). Leukemia. 17(5). 859–868. 31 indexed citations

13.

Suciu, Stefan, T de Witte, Franco Mandelli, et al.. (2002). Allogeneic vs autologous stem cell transplantation according to cytogenetic and FAB features in AML patients (pts) <=45 yrs old in CRI: Results of the EORTC-GIMEMA AML-10 trial. Bone Marrow Transplantation. 29. 2 indexed citations

14.

Belhabri, Amine, Xavier Thomas, Eric Wattel, et al.. (2002). All trans retinoic acid in combination with intermediate-dose cytarabine and idarubicin in patients with relapsed or refractory non promyelocytic acute myeloid leukemia: a phase II randomized trial. The Hematology Journal. 3(1). 49–55. 28 indexed citations

15.

Suciu, Stefan, R Zittoun, Franco Mandelli, et al.. (2001). Allogeneic vs autologous stem cell transplantation according to cytogenetic features in AML patients (pts) <= 45 yrs old in first CR: Results of the EORTC-GIMEMA AML-10 trial. Blood. 98(11). 5 indexed citations

16.

Belhabri, Amine, Xavier Thomas, Jacques Troncy, et al.. (1999). Continuous-Infusion Carboplatin in Combination with Idarubicin or Mitoxantrone for High-Risk Acute Myeloid Leukemia: A Randomised Phase II Study. Leukemia & lymphoma. 36(1-2). 45–55. 5 indexed citations

17.

Michallet, Mauricette, Amine Belhabri, Lysiane Molina, et al.. (1999). Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation. Bone Marrow Transplantation. 23(2). 145–150. 16 indexed citations

18.

Michallet, M., Florence Persat, N Kranzhöfer, et al.. (1998). Pharmacokinetics of itraconazole oral solution in allogeneic bone marrow transplant patients receiving total body irradiation. Bone Marrow Transplantation. 21(12). 1239–1243. 27 indexed citations

19.

Archimbaud, E, Mauricette Michallet, I Philip, et al.. (1997). Granulocyte colony‐stimulating factor given in addition to interferon‐α to mobilize peripheral blood stem cells for autologous transplantation in chronic myeloid leukaemia. British Journal of Haematology. 99(3). 678–684. 14 indexed citations

20.

Thomas, Xavier, Bruno Anglaret, Anne Thiébaut, et al.. (1997). Improvement of prognosis in refractory and relapsed acute promyelocytic leukemia over recent years: the role of all- trans retinoic acid therapy. Annals of Hematology. 75(5-6). 195–200. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact